Semax Nasal Spray in Canada: Intranasal Peptide Delivery and the Science Behind It (2026)

Of all the delivery formats used in peptide research, intranasal administration occupies a unique position. It offers a direct anatomical route to the central nervous system, bypassing obstacles that make other delivery methods far less suitable for CNS-targeted peptides. Semax — a synthetic heptapeptide derived from adrenocorticotropic hormone (ACTH) — has been studied in nasal spray format for decades, first in Russian clinical research and more recently in the broader international research peptide community. For Canadian researchers working in cognitive biology, neuroprotection, or peptide pharmacokinetics, understanding both the science of Semax and the rationale for intranasal delivery is fundamental.

This article examines what Semax is, why the nasal spray format matters scientifically, what the research shows about its mechanisms, and how to approach quality sourcing of research peptides in Canada.

What Is Semax?

Semax is a synthetic heptapeptide with the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was developed from the ACTH(4–10) fragment by researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences, with the specific goal of isolating cognitive and neuroprotective activity while eliminating the steroidogenic effects of the parent hormone.

The structural design of Semax reflects deliberate molecular engineering. Its N-terminus contains the ACTH(4–7) tetrapeptide sequence (Met-Glu-His-Phe), which is responsible for much of its CNS activity. Its C-terminus incorporates the tripeptide Pro-Gly-Pro, a naturally occurring brain peptide that significantly increases metabolic stability by protecting against enzymatic degradation. This stability enhancement is one reason Semax has remained a durable subject of research peptide study — it resists breakdown long enough to interact meaningfully with CNS targets.

Semax was approved as a prescription medication in Russia in the 1990s, where it has been prescribed for stroke recovery, optic nerve disease, and cognitive impairment. In Canada and most Western countries, Semax is available for research use only and is not approved for human therapeutic application.

Why Intranasal? The Science of Nose-to-Brain Delivery

The most critical factor shaping Semax's delivery format is the blood-brain barrier (BBB). The BBB is a highly selective semi-permeable border between the bloodstream and the brain, formed by tight junctions between endothelial cells lining cerebral capillaries. For most peptides, this barrier is an insurmountable obstacle: oral administration results in near-zero CNS bioavailability due to peptidase degradation in the gut, and intravenous delivery leaves most of the peptide unable to cross into the brain parenchyma.

Intranasal delivery exploits the unique anatomy of the olfactory region. The olfactory epithelium — located at the roof of the nasal cavity — is one of the few places in the body where neurons directly interface with the external environment. Olfactory receptor neurons project through the cribriform plate of the ethmoid bone directly into the olfactory bulb of the brain. This perineural pathway allows small molecules and peptides to bypass the BBB entirely, travelling along axonal sheaths into the CNS.

Research in rodent models has demonstrated that Semax reaches brain tissue within minutes of intranasal administration via this olfactory pathway. Cerebrospinal fluid (CSF) concentrations rise within approximately 30 minutes of dosing, and peak CNS concentrations have been reported to reach roughly 60 to 70 percent of corresponding plasma concentrations in animal studies — a remarkable ratio compared to BBB-limited alternatives. The trigeminal nerve pathway provides a secondary intranasal route, further broadening CNS distribution.

For peptide researchers studying CNS pharmacokinetics, the nose-to-brain model that Semax exemplifies is itself an active area of drug delivery science. Semax serves as both a research target and a model compound for understanding intranasal peptide transport mechanisms.

Key Mechanisms of Action

BDNF and NGF Upregulation

The most consistently reported mechanism of Semax in research models is the upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). Neurotrophins are proteins essential for the growth, maintenance, and survival of neurons. BDNF in particular plays a central role in synaptic plasticity — the ability of synaptic connections to strengthen or weaken over time in response to activity — which underlies learning and memory at the cellular level. Semax studies have shown enhanced BDNF expression in the hippocampus and cortex following administration, alongside activation of TrkB receptor signalling pathways downstream of BDNF binding.

Dopaminergic and Serotonergic Modulation

Research has also identified Semax-associated changes in monoamine neurotransmitter systems. Studies have observed enhancement of dopamine and serotonin synthesis in prefrontal circuits, regions heavily implicated in working memory, executive function, and motivated cognition. This monoaminergic dimension of Semax research adds a complementary layer to the neurotrophin pathway findings, suggesting the peptide engages multiple CNS targets simultaneously.

ACTH-Fragment Effects on Attentional Systems

The ACTH-derived portion of the Semax sequence has its own research history. ACTH fragments have been shown to modulate acetylcholine-mediated attentional systems in rodent models, influencing processes such as sustained attention, response selection, and sensory gating. Because Semax retains this N-terminal fragment while stripping out the steroidogenic activity of full ACTH, researchers can study these attentional system effects without the confound of cortisol and corticosterone changes that ACTH itself would produce.

Neuroprotection and Ischemia Research

Some of the most robust Semax research has come from cerebrovascular injury models. Studies using rat models of cerebral ischemia-reperfusion injury — published in peer-reviewed literature and indexed on PubMed — have documented that Semax affects the brain transcriptome in ways consistent with neuroprotection: enhanced expression of neurotrophins and their receptors, suppression of pro-inflammatory gene expression, and preservation of neurotransmission-related gene networks that would otherwise be downregulated following ischemic insult. A 2025 study by Tomasello et al. further explored Semax's role as a copper-chelating peptide, demonstrating reduced copper-catalyzed reactive oxygen species production — an oxidative stress mechanism implicated in neurodegenerative pathways.

Semax Nasal Spray vs. Injectable: What Research Protocols Use

In research contexts, Semax is studied in two primary formats: intranasal (nasal spray) and subcutaneous injection. The intranasal route is by far the most prevalent in published literature and in research peptide supply, for several reasons:

• CNS targeting efficiency: The olfactory pathway provides direct nose-to-brain transport not available via subcutaneous injection, where the peptide must still cross the BBB from systemic circulation.
• Metabolic stability: The Pro-Gly-Pro stabilization built into Semax's structure was specifically engineered to preserve peptide integrity during intranasal delivery and transport.
• Research precedent: Decades of published Semax research, including the Russian clinical trials that led to prescription approval, used intranasal delivery. This precedent makes intranasal the better-characterized route for comparative research.
• Practical considerations: Nasal spray formats allow non-invasive administration in animal models and simplified handling in laboratory settings.

Injectable Semax is studied in some research contexts, particularly where peripheral bioavailability is the variable of interest rather than CNS uptake. However, for neuroscience-focused peptide research, the intranasal format is the standard.

Semax and the Canadian Research Context

In Canada, Semax is not approved by Health Canada for human therapeutic use. It is not classified as a controlled substance under the Controlled Drugs and Substances Act, and it is legally accessible for acquisition and possession in the context of legitimate scientific research. As with all research peptides in Canada, it must be clearly intended for research purposes only — not for human or veterinary use.

Canadian interest in intranasal peptide delivery is also growing in the academic literature, as researchers at Canadian universities explore nose-to-brain drug delivery for CNS conditions including Alzheimer's disease, Parkinson's disease, and acute brain injury. Semax, as one of the most studied intranasal peptides with an established mechanism and published safety profile in animal models, occupies a natural position in this research landscape.

Researchers at Canadian institutions should ensure that any peptide acquisition complies with their institution's ethics board requirements and research protocols. Helix Core Labs supplies research peptides exclusively to qualified researchers operating within a legitimate research framework.

What to Look for in a Semax Nasal Spray Research Product

The intranasal format introduces specific quality considerations beyond those applicable to injectable peptides. When evaluating Semax nasal spray for research, Canadian researchers should look for:

• Third-party Certificate of Analysis (CoA): Every batch should be independently verified by HPLC for purity and mass spectrometry for molecular identity confirmation. An in-house CoA without independent verification is insufficient for research-grade supply.
• Sterile formulation: Research-grade Semax nasal spray should be formulated under sterile conditions. The excipient solution (typically isotonic saline or bacteriostatic water) and the spray mechanism both matter for delivery consistency.
• Appropriate concentration and volume: Nasal spray research products are typically supplied at concentrations of 0.1% or higher in volumes of 3–10 mL. Verify that the format is appropriate for your specific research protocol.
• Proper storage and cold-chain handling: Semax nasal spray should be stored at 2–8°C and protected from light. Suppliers should demonstrate appropriate cold-chain handling during shipping to preserve peptide integrity.
• Transparent labelling: Products must be clearly labelled for research use only, with lot numbers traceable to third-party test results.

At Helix Core Labs, our Semax nasal spray is formulated for research applications and supplied with a full Certificate of Analysis. We are committed to providing Canadian researchers with the highest purity research peptides, backed by transparent third-party verification. Explore our peptide catalog at helixcorelabs.ca.

Conclusion

Semax nasal spray represents one of the most scientifically grounded applications of intranasal peptide delivery in current research. Its molecular design — combining ACTH-derived CNS activity with engineered metabolic stability — makes it well-suited to the intranasal route, and decades of published research support both its mechanisms and its pharmacokinetic profile. For Canadian researchers working in neuroscience, cognitive biology, or peptide pharmacology, Semax in nasal spray format is a well-characterized and highly relevant research compound.

Understanding the delivery science is as important as understanding the peptide itself. The nose-to-brain pathway that makes Semax nasal spray scientifically compelling is also a window into broader questions about CNS drug delivery — an area of growing importance in Canadian and global neuroscience research.

Helix Core Labs offers research-grade Semax nasal spray for qualified Canadian researchers. Visit helixcorelabs.ca to browse our full catalog of third-party tested research peptides.

All products sold by Helix Core Labs are intended for research use only and are not approved for human or veterinary use. This article is for informational purposes only and does not constitute medical advice.